Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes

Diabetes Res Clin Pract. 2024 Apr:210:111612. doi: 10.1016/j.diabres.2024.111612. Epub 2024 Mar 11.

Abstract

Globally ≈10% of adults have diabetes, with 80% in disadvantaged regions, hence low-cost renoprotective agents are desirable. Fenofibrate demonstrated microvascular benefits in several cardiovascular end-point diabetes trials, but knowledge of effects in late-stage kidney disease is limited. We report new FIELD substudy data and call for further kidney outcomes data.

MeSH terms

  • Cardiovascular Diseases*
  • Diabetes Mellitus, Type 2* / drug therapy
  • Fenofibrate* / therapeutic use
  • Humans
  • Hypolipidemic Agents / therapeutic use
  • Kidney

Substances

  • Fenofibrate
  • Hypolipidemic Agents